Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL
Open Access
- 26 November 2022
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 28 (1) , 1-19
Abstract
Background: Tetrandrine, a bisbenzylisoquinoline (BBI) alkaloid extracted from Stephania tetrandra (S. Moore), and is widely used in several diseases such as tuberculosis, hyperglycemia, malaria, and tumors. Tetrandrine was recently shown to prevent bone loss in ovariectomized mice. However, the specific mechanism underlying osteoclastogenesis inhibition remains unclear. Methods: Tetrandrine’s cytotoxicity to cells was determined using the Cell Counting Kit-8 assay. Tartrate-resistant acid phosphatase staining, immunofluorescence and bone resorption assay were performed to evaluate osteoclasts’ differentiation and absorption capacity. The bone-forming capacity was assessed using alkaline phosphatase and Alizarin red S staining. qPCR and Western blotting were applied to assess the related genes and protein expression. Tetrandrine’s impact on TRAIL was demonstrated through a co-immunoprecipitation assay. Animal experiments were performed for the detection of the therapeutic effect of Tetrandrine on osteoporosis. Results: Tetrandrine attenuated RANKL-induced osteoclastogenesis and decreased the related gene expression. The co-immunoprecipitation assay revealed that Tetrandrine administration accelerated the ubiquitination of TNF-related apoptosis-inducing ligand (TRAIL), which was subsequently degraded. Moreover, TRAIL overexpression was found to partially reverse the Tetrandrine-induced inhibition of osteoclastogenesis. Meanwhile, Tetrandrine significantly inhibited the phosphorylation of p38, p65, JNK, IKBα and IKKα/β, while the TRAIL overexpression weakened this effect. In addition, Tetrandrine promoted osteogenesis and inhibited the TRAIL expression in osteoblasts. Tetrandrine consistently improved bone destruction by stimulating bone formation and inhibiting bone resorption in an OVX-induced mouse model. Conclusion: Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting TRAIL degradation and promotes osteoblast differentiation, suggesting its potential in antiosteopenia pharmacotherapy.Keywords
Funding Information
- Zhejiang Provincial Natural Science Foundation of China (LGF22H060003)
This publication has 38 references indexed in Scilit:
- Novel Conjugation of Tumor‐Necrosis‐Factor‐Related Apoptosis‐Inducing Ligand (TRAIL) with Monomethyl Auristatin E for Efficient Antitumor Drug DeliveryAdvanced Materials, 2013
- Norisoboldine Suppresses Osteoclast Differentiation through Preventing the Accumulation of TRAF6-TAK1 Complexes and Activation of MAPKs/NF-κB/c-Fos/NFATc1 PathwaysPLOS ONE, 2013
- Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclastsJournal of Bone and Mineral Research, 2013
- TRAF-6 Dependent Signaling Pathway Is Essential for TNF-Related Apoptosis-Inducing Ligand (TRAIL) Induces Osteoclast DifferentiationPLOS ONE, 2012
- Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone lossClinical Interventions in Aging, 2010
- Cellular and Molecular Mechanisms of Bone RemodelingJournal of Biological Chemistry, 2010
- A large-conductance (BK) potassium channel subtype affects both growth and mineralization of human osteoblastsAmerican Journal of Physiology-Cell Physiology, 2009
- The NF-κB-independent functions of IKK subunits in immunity and cancerTrends in Cell Biology, 2009
- NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1Journal of Biological Chemistry, 2007
- Osteoclast differentiation and activationNature, 2003